Operating Segments (Details) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended
Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Summary of segmental information
Revenues, Principally from Grants	$ 2,787,709us-gaap_Revenues	$ 312,491us-gaap_Revenues	$ 5,116,554us-gaap_Revenues	$ 1,845,123us-gaap_Revenues	$ 3,224,152us-gaap_Revenues	$ 3,144,620us-gaap_Revenues
Income/ (Loss) from Operations	(5,141,378)us-gaap_OperatingIncomeLoss	(1,860,662)us-gaap_OperatingIncomeLoss	(8,427,118)us-gaap_OperatingIncomeLoss	(5,704,443)us-gaap_OperatingIncomeLoss	(7,156,542)us-gaap_OperatingIncomeLoss	(4,690,668)us-gaap_OperatingIncomeLoss
Amortization and Depreciation Expense	61,468	58,100	183,960	171,666	230,071	230,630
Interest Income	428us-gaap_InvestmentIncomeInterest	652us-gaap_InvestmentIncomeInterest	1,041us-gaap_InvestmentIncomeInterest	1,438us-gaap_InvestmentIncomeInterest	1,960us-gaap_InvestmentIncomeInterest	6,202us-gaap_InvestmentIncomeInterest
Stock-Based Compensation	160,995us-gaap_ShareBasedCompensation	406,891us-gaap_ShareBasedCompensation	458,914us-gaap_ShareBasedCompensation	571,171us-gaap_ShareBasedCompensation	803,060us-gaap_ShareBasedCompensation	462,170us-gaap_ShareBasedCompensation
Identifiable Assets	6,272,942us-gaap_Assets		6,272,942us-gaap_Assets		8,265,455us-gaap_Assets	4,705,104us-gaap_Assets
Vaccines/BioDefense [Member]
Summary of segmental information
Revenues, Principally from Grants	2,729,854	264,920	4,928,284	1,683,265	3,003,822	2,919,677
Income/ (Loss) from Operations	545,728	(419,929)	949,032	(1,983,396)	(1,666,130)	(33,636)
Amortization and Depreciation Expense	9,922	28,316	29,666	83,951	37,981	38,589
Stock-Based Compensation	17,224	39,493	38,124	61,742	80,432	44,484
Identifiable Assets	1,566,050		1,566,050		1,870,414	628,494
BioTherapeutics [Member]
Summary of segmental information
Revenues, Principally from Grants	57,855	47,571	188,270	161,858	220,330	224,943
Income/ (Loss) from Operations	(4,855,765)	(1,080,436)	(6,541,832)	(2,068,703)	(3,069,998)	(2,203,721)
Amortization and Depreciation Expense	49,985	29,233	148,995	86,303	190,033	190,003
Stock-Based Compensation	33,118	158,142	142,374	205,083	250,431	84,020
Identifiable Assets	265,939		265,939		386,721	566,111
Corporate [Member]
Summary of segmental information
Income/ (Loss) from Operations	(831,341)	(360,297)	(2,834,318)	(1,652,344)	(2,420,414)	(2,453,311)
Amortization and Depreciation Expense	1,561	551	5,299	1,412	2,057	2,038
Interest Income	791,823	(4,699,194)	(202,662)	(5,347,984)	1,960	6,202
Stock-Based Compensation	110,653	209,256	278,416	304,346	472,197	333,666
Identifiable Assets	$ 4,440,953		$ 4,440,953		$ 6,008,320	$ 3,510,499

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name:	us-gaap_Assets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name:	us-gaap_DepreciationDepletionAndAmortization
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_InvestmentIncomeInterest
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_SegmentReportingInformationProfitLossAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name:	us-gaap_ShareBasedCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=sngx_BioTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=sngx_VaccinesBioDefenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: